Fluclotizolam

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Aethyta (talk | contribs) at 15:37, 31 October 2019. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Fluclotizolam
Legal status
Legal status
Identifiers
  • 2-chloro-4-(2-fluorophenyl)-9-methyl-4H-thieno[3,2-f] [1,2,4]triazolo[4,3-a] [1,4]diazepine
PubChem CID
Chemical and physical data
FormulaC15H10ClFN4S
Molar mass332.78 g·mol−1
3D model (JSmol)
  • Fc4ccccc4C2=NCc1nnc(C)n1c3sc(Cl)cc23
  • InChI=1S/C15H10ClFN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3
  • Key:ZDYRCUZZLRLMHG-UHFFFAOYSA-N

Fluclotizolam is a thienotriazolodiazepine derivative which was first synthesised in 1979,[1] but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in 2017.[2][3][4]


See also

References

  1. ^ Hellerbach J, et al. Thienotriazolodiazepine derivatives. Patent US 4155913
  2. ^ Zawilska JB, Wojcieszak J. An expanding world of New Psychoactive Substances – Designer benzodiazepines. NeuroToxicology 2019 July; 73: 8-16. doi:10.1016/j.neuro.2019.02.015
  3. ^ Moosmann B., Auwärter V. (2018) Designer Benzodiazepines: Another Class of New Psychoactive Substances. In: Maurer H., Brandt S. (eds) New Psychoactive Substances. Handbook of Experimental Pharmacology, vol 252. doi:10.1007/164_2018_154
  4. ^ Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P. Les designer benzodiazepines: qu’en sait-on aujourd’hui?. Toxicologie Analytique et Clinique. 2018 Feb 1;30(1):5-18. doi:10.1016/j.toxac.2017.12.001